Andreas Rosenwald

Papers

Total Citations

H-Index

About

Andreas Rosenwald is a pioneer at the intersection of robotics and tissue engineering, whose work is reshaping the future of drug testing. His primary research focuses on developing automated, animal-free platforms for producing 3D epithelial tissues, directly addressing the global shift away from mandatory animal testing. His most notable contribution, the “ReBiA—Robotic Enabled Biological Automation” system, represents a breakthrough in scalable, high-throughput tissue production, enabling more ethical and human-relevant preclinical models. This work has garnered significant attention, with his key 2024 publication already accumulating 13 citations, underscoring its immediate impact in a rapidly evolving regulatory landscape. By aligning with the FDA’s recent decision to eliminate mandatory animal testing and the European Parliament’s push for faster transitions, Rosenwald’s innovations are not only scientifically robust but also strategically timed to meet public and policy demands. His research stands at the forefront of a paradigm shift, offering a tangible path toward replacing animal models with advanced, automated biological systems that promise greater accuracy and ethical integrity in drug development.